Abrdn Life Sciences Investors
$16.52
$-0.25 (-1.49%)
Jan 5, 2026
Price History (1Y)
Analysis
Abrdn Life Sciences Investors is a company within the Financial Services sector and Asset Management industry. It has a market capitalization of $488.97M. The financial health of Abrdn Life Sciences Investors reveals significant profitability, with gross margins at 100.0% and operating margins at -346.8%. However, this is accompanied by negative net income, with a net loss of $85.59M in the trailing twelve months. The company's returns on equity (ROE) stand at 17.6%, but it has a negative return on assets (ROA) of -0.4%. Cash and cash equivalents amount to $75,538, while free cash flow was -$2,176,220. Abrdn Life Sciences Investors' valuation metrics include a price-to-book ratio of 0.95 and a price-to-sales ratio of 252.26. The company's earnings growth has been substantial, with an increase of 259.4% year-over-year. The dividend yield is notably high at 1085.0%, but the payout ratio is relatively moderate at 65.2%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Key Statistics
- Market Cap
- $488.97M
- P/E Ratio
- 6.01
- 52-Week High
- $17.80
- 52-Week Low
- $10.55
- Avg Volume
- 172.03K
- Beta
- 0.72
- Dividend Yield
- 1085.00%
Company Info
- Industry
- Asset Management
- Exchange
- NYQ
- Country
- United States